blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2242840

EP2242840 - RECOMBINANT ADENO-ASSOCIATED VIRUS PRODUCTION USING BHK CELLS IN SUSPENSION [Right-click to bookmark this link]
Former [2010/43]RECOMBINANT VIRUS PRODUCTION USING MAMMALIAN CELLS IN SUSPENSION
[2019/04]
StatusNo opposition filed within time limit
Status updated on  10.07.2020
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  21.06.2019
FormerGrant of patent is intended
Status updated on  19.02.2019
FormerExamination is in progress
Status updated on  08.09.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Applied Genetic Technologies Corporation
11801 Research Drive, Suite D
Alachua, FL 32615 / US
[2019/30]
Former [2010/43]For all designated states
Applied Genetic Technologies Corporation
11801 Research Drive Suite D
Alachua, FL 32615 / US
Inventor(s)01 / KNOP, Dave
3660 NW 64th Lane
Gainesville, FL 32653 / US
02 / THOMAS, Darby
2388 NW 145th Drive
Newberry, FL 32669 / US
03 / VERES, Gabor
8117 SW 72nd Place
Gainesville, FL 32608 / US
 [2010/43]
Representative(s)Hiebl, Inge Elisabeth
Kraus & Weisert
Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
[2019/30]
Former [2010/43]Hiebl, Inge Elisabeth
Kraus & Weisert Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15
80539 München / DE
Application number, filing date09706778.929.01.2009
[2010/43]
WO2009US00577
Priority number, dateUS20080062819P29.01.2008         Original published format: US 62819 P
[2010/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009097129
Date:06.08.2009
Language:EN
[2009/32]
Type: A1 Application with search report 
No.:EP2242840
Date:27.10.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 06.08.2009 takes the place of the publication of the European patent application.
[2010/43]
Type: B1 Patent specification 
No.:EP2242840
Date:24.07.2019
Language:EN
[2019/30]
Search report(s)International search report - published on:US06.08.2009
(Supplementary) European search report - dispatched on:EP21.11.2012
ClassificationIPC:C12N7/00, C12N7/02, C12N15/86
[2010/43]
CPC:
C07K14/005 (EP,US); C12N15/8645 (US); C12N15/86 (EP,US);
C12N7/00 (EP,US); A61K48/00 (EP,US); C12N2710/16643 (EP,US);
C12N2710/16662 (EP,US); C12N2750/14122 (EP,US); C12N2750/14143 (EP,US);
C12N2800/50 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2019/30]
Former [2010/43]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:REKOMBINANTE ADENO-ASSOZIIERTE VIRUSPRODUKTION MIT BHK ZELLEN IN SUSPENSION[2019/04]
English:RECOMBINANT ADENO-ASSOCIATED VIRUS PRODUCTION USING BHK CELLS IN SUSPENSION[2019/04]
French:PRODUCTION DE VIRUS ADENO ASSOCIE RECOMBINANTS À L'AIDE DE CELLULES BHK EN SUSPENSION[2019/04]
Former [2010/43]REKOMBINANTE VIRUSPRODUKTION MIT SÄUGERZELLEN IN SUSPENSION
Former [2010/43]RECOMBINANT VIRUS PRODUCTION USING MAMMALIAN CELLS IN SUSPENSION
Former [2010/43]PRODUCTION DE VIRUS RECOMBINANTS À L'AIDE DE CELLULES DE MAMMIFÈRE EN SUSPENSION
Entry into regional phase30.08.2010National basic fee paid 
30.08.2010Search fee paid 
30.08.2010Designation fee(s) paid 
30.08.2010Examination fee paid 
Examination procedure30.08.2010Examination requested  [2010/43]
14.06.2013Amendment by applicant (claims and/or description)
23.02.2016Despatch of a communication from the examining division (Time limit: M06)
11.08.2016Reply to a communication from the examining division
29.08.2017Despatch of a communication from the examining division (Time limit: M06)
06.04.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
10.04.2018Reply to a communication from the examining division
10.08.2018Despatch of a communication from the examining division (Time limit: M04)
10.12.2018Reply to a communication from the examining division
20.02.2019Communication of intention to grant the patent
13.06.2019Fee for grant paid
13.06.2019Fee for publishing/printing paid
13.06.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.02.2016
Opposition(s)03.06.2020No opposition filed within time limit [2020/33]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
10.04.2018Request for further processing filed
10.04.2018Full payment received (date of receipt of payment)
Request granted
20.04.2018Decision despatched
Fees paidRenewal fee
25.01.2011Renewal fee patent year 03
25.01.2012Renewal fee patent year 04
25.01.2013Renewal fee patent year 05
27.01.2014Renewal fee patent year 06
27.01.2015Renewal fee patent year 07
27.01.2016Renewal fee patent year 08
27.01.2017Renewal fee patent year 09
29.01.2018Renewal fee patent year 10
28.01.2019Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.01.2009
CY24.07.2019
CZ24.07.2019
EE24.07.2019
FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
MK24.07.2019
MT24.07.2019
PL24.07.2019
RO24.07.2019
SE24.07.2019
SI24.07.2019
SK24.07.2019
TR24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
[2022/32]
Former [2022/27]HU29.01.2009
CY24.07.2019
CZ24.07.2019
EE24.07.2019
FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
MT24.07.2019
PL24.07.2019
RO24.07.2019
SE24.07.2019
SI24.07.2019
SK24.07.2019
TR24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/37]CZ24.07.2019
EE24.07.2019
FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
PL24.07.2019
RO24.07.2019
SE24.07.2019
SI24.07.2019
SK24.07.2019
TR24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/36]CZ24.07.2019
EE24.07.2019
FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
PL24.07.2019
RO24.07.2019
SE24.07.2019
SK24.07.2019
TR24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/25]CZ24.07.2019
EE24.07.2019
FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
PL24.07.2019
RO24.07.2019
SE24.07.2019
SK24.07.2019
TR24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
PT25.11.2019
IS24.02.2020
Former [2020/24]EE24.07.2019
FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
PL24.07.2019
RO24.07.2019
SE24.07.2019
TR24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
PT25.11.2019
IS24.02.2020
Former [2020/23]EE24.07.2019
FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
PL24.07.2019
RO24.07.2019
SE24.07.2019
TR24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/22]EE24.07.2019
FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
SE24.07.2019
TR24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/17]FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
SE24.07.2019
TR24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/12]FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
SE24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/11]FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
SE24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
PT25.11.2019
Former [2020/10]FI24.07.2019
LT24.07.2019
SE24.07.2019
BG24.10.2019
NO24.10.2019
PT25.11.2019
Former [2020/09]FI24.07.2019
LT24.07.2019
NO24.10.2019
Former [2020/08]LT24.07.2019
NO24.10.2019
Documents cited:Search[XI] US2007202587  (HWANG KYU-KYE et al.) [X] 1-12 * cited in ISR, the whole document; paragraph [0143] *[I] 13,14
 [XI]   M J BOOTH ET AL: "Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids", GENE THERAPY, vol. 11, no. 10, 1 May 2004 (2004-05-01), pages 829 - 837, XP055041073, ISSN: 0969-7128, DOI: 10.1038/sj.gt.3302226 [X] 1,2,4-10,12 * the whole document *[I] 13,14

DOI:   http://dx.doi.org/10.1038/sj.gt.3302226
 [X]   DUROCHER ET AL: "Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells", JOURNAL OF VIROLOGICAL METHODS, ELSEVIER BV, NL, vol. 144, no. 1-2, 27 July 2007 (2007-07-27), pages 32 - 40, XP022170236, ISSN: 0166-0934, DOI: 10.1016/J.JVIROMET.2007.03.014 [X] 11,12 * abstract *

DOI:   http://dx.doi.org/10.1016/j.jviromet.2007.03.014
 [X]   DAVID R. KNOP ET AL: "Bioreactor Production of Recombinant Herpes Simplex Virus Vectors", BIOTECHNOLOGY PROGRESS, vol. 23, no. 3, 1 January 2007 (2007-01-01), pages 715 - 721, XP055041050, ISSN: 8756-7938, DOI: 10.1021/bp060373p [X] 1,2,4-10,12 * abstract *

DOI:   http://dx.doi.org/10.1021/bp060373p
 [X]   MARKUS HILDINGER ET AL: "High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells", BIOTECHNOLOGY LETTERS, SPRINGER NETHERLANDS, DORDRECHT, vol. 29, no. 11, 17 July 2007 (2007-07-17), pages 1713 - 1721, XP019523980, ISSN: 1573-6776, DOI: 10.1007/S10529-007-9441-3 [X] 11,12 * the whole document *

DOI:   http://dx.doi.org/10.1007/s10529-007-9441-3
 [X]   JOON YOUNG PARK ET AL: "Scalable production of adeno-associated virus type 2 vectors via suspension transfection", BIOTECHNOLOGY AND BIOENGINEERING, vol. 94, no. 3, 20 June 2006 (2006-06-20), pages 416 - 430, XP055041067, ISSN: 0006-3592, DOI: 10.1002/bit.20776 [X] 1,2,4-10,12 * the whole document *

DOI:   http://dx.doi.org/10.1002/bit.20776
 [A]   PERRIN P ET AL: "An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system", VACCINE, ELSEVIER LTD, GB, vol. 13, no. 13, 1 January 1995 (1995-01-01), pages 1244 - 1250, XP004057477, ISSN: 0264-410X, DOI: 10.1016/0264-410X(94)00022-F [A] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1016/0264-410X(94)00022-F
 [T]   NATHALIE CLMENT ET AL: "Large-Scale Adeno-Associated Viral Vector Production Using a Herpesvirus-Based System Enables Manufacturing for Clinical Studies", HUMAN GENE THERAPY, vol. 20, no. 8, 1 August 2009 (2009-08-01), pages 796 - 806, XP055041035, ISSN: 1043-0342, DOI: 10.1089/hum.2009.094 [T] * the whole document *

DOI:   http://dx.doi.org/10.1089/hum.2009.094
 [T]   DARBY L. THOMAS ET AL: "Scalable Recombinant Adeno-Associated Virus Production Using Recombinant Herpes Simplex Virus Type 1 Coinfection of Suspension-Adapted Mammalian Cells", HUMAN GENE THERAPY, vol. 20, no. 8, 1 August 2009 (2009-08-01), pages 861 - 870, XP055043924, ISSN: 1043-0342, DOI: 10.1089/hum.2009.004 [T] * the whole document *

DOI:   http://dx.doi.org/10.1089/hum.2009.004
International search[Y]   WURM.: "Production of recombinant protein therapeutics in cultivated mammalian cells.", NATURE BIOTECHNOLOGY., vol. 22, 2004, pages 1393 - 1398, XP002514352 [Y]

DOI:   http://dx.doi.org/10.1038/nbt1026
by applicantUS2007202587
 US50377507
 US25218202
 US7091029
 US2007172846
 US50377506
   GRAHAM, J., GEN. VIROL., vol. 68, 1987, pages 937 - 940
   GAMIER ET AL., CYTOTECHNOLOGY, vol. 15, no. 1-3, 1994, pages 145 - 155
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.